WHIM Syndrome Market Size, Share, and Industry Analysis, By Drug (XOLREMDI (Mavorixafor) and Others), By Distribution Channel (Specialty Pharmacy, Hospital Pharmacy, and Others), and Regional Forecast, 2026-2034

The WHIM syndrome market is witnessing substantial growth due to significant development and approvals by regulatory bodies to boost the product launch and availability for treatment. Warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis are collectively known as WHIM Syndrome (WHIM). It is an ultra-rare and challenging-to-diagnose primary immunodeficiency (PI). The patient suffering from the syndrome does not have a proper functional immune system. This leads to difficulty in combating infections, especially respiratory, ear, and skin infections. WHIM syndrome is extremely rare, and its exact prevalence is unknown, although it has been estimated at 1 in 5 million live births. Approximately 60 cases have been reported in the medical literature. Established players are focusing on organizational restructuring to streamline their focus on the development of therapies for the ultra-rare disorder.

• For instance, in February 2025, X4 Pharmaceuticals restructured its workforce and capital spending to streamline its strategic efforts for advancement and promotion of mavorixafor to XOLREMDI, approved for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a rare immunodeficient disease.

WHIM Syndrome Market Driver

Approval by Regulatory Bodies in Key Markets to Drive Support Market Growth

Until recently, there was no approved treatment regimen for WHIM syndrome. The development of targeted therapy for WHIM syndrome was a significant milestone. Approval for these targeted therapies is anticipated to drive the growth of the global market in the forecasted years.

• For instance, in January 2025, the company received the European Medicines Agency’s (EMA) validation of Marketing Authorization Application (MAA) for Mavorixafor, with a decision expected by 2026. Such developments are expected to drive the market growth further. 

Mean Age of Clinical Representation of Probable WHIM Study Subjects (Years)

In August 2022, NIH published an article titled ‘Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients’. The article reported that the mean age of clinical manifestation of warts was 12 years.

WHIM Syndrome Market Restraint

Challenges in the Diagnosis of WHIM Syndrome to Impede the Market Growth

The WHIM Syndrome is an ultra-rare disease. The diagnosis of the disease is difficult due to the small sample size and limited knowledge base for the disease. People living with WHIM syndrome may exhibit different symptoms that further contribute to misdiagnosis. Some may only have mild symptoms, whereas others may develop potentially life-threatening complications.

• For instance, the Immune Deficiency Foundation reported that most individuals with WHIM syndrome are first misdiagnosed with common variable immune deficiency (CVID) or a more common type of neutropenia. Many people living with WHIM syndrome had frequent infections as children and were often misdiagnosed for many years. Such challenges in diagnosis restrict the treatment and impede the market growth.

WHIM Syndrome Market Opportunity

Research and Development Activities to Increase Safety to Provide Significant Growth Opportunity

The safety and tolerability of the drug approved for this disease are still in doubt. Research and development activities to enhance its safety and tolerability provide a growth opportunity. With enhanced safety features, greater product adoption is facilitated.

• For instance, in October 2024, X4 Pharmaceuticals showcased data from its clinical trial titled ‘A Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients with WHIM Syndrome’ to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Such research initiatives are expected to provide robust growth avenues for the market.

Key Insights

The report covers the following key insights:

• Epidemiology of WHIM Diseases, By Key Countries/ Regions, 2024
• Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
• Regulatory & Reimbursement Scenario, By Key Countries/ Regions

Segmentation

Analysis by Drug

By Drug, the market is divided into XOLREMDI (Mavorixafor) and Others.

The XOLREMDI (Mavorixafor) segment is expected to hold a dominant position in the global WHIM syndrome market based on the drug. The high market share of the drug is due to approval by key regulatory agencies in key markets such as North America. 

• For instance, in April 2024, X4 Pharmaceuticals received FDA approval of mavorixafor, marketed in the U.S. under the name XOLREMDI, for use as an oral, once-daily therapy in patients 12 years of age and older. The drug is indicated for patients with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes. Such developments are expected to fuel the market growth. 

 Analysis by Distribution Channel

By distribution channel, the market is divided into specialty pharmacy, hospital pharmacy, and others.

Specialty pharmacy is expected to hold a significant market share. The high market share of specialty pharmacies is due to an exclusive partnership with pharmaceutical companies to provide treatment and meet the clinical needs of patients with this rare disease.

• For instance, in April 2024, X4 Pharmaceuticals, Inc., collaborated with PANTHERx to provide treatment medication for WHIM Syndrome. After completion of the enrollment form, the specialty pharmacy verifies coverage and directly ships to patients. Such strategic collaborations are expected to drive the growth of the segment. 

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global WHIM syndrome market in 2024. The growth of the market in the region is attributed to high investment funds, strategic collaboration for research, robust presence of key players in the region, and regulatory approvals by governing bodies. 

• For instance, in May 2024, X4 Pharmaceuticals, Inc. launched Mavorixafor, marketed under the name of XOLREMDI in the U.S. Such developments are expected to drive the market.

Europe is expected to hold a considerable market share in the forecast period of the global WHIM syndrome market. The region's high market share is due to strategic collaboration with specialty pharmacies for distribution in the region.

• For instance, in January 2025, Norgine, a European specialist pharmaceutical company, collaborated with X4 Pharmaceuticals, Inc., and signed an exclusive licensing and supply agreement under which Norgine is expected to commercialize mavorixafor in Europe following regulatory approvals.

Asia Pacific is expected to grow with a significant CAGR during the forecast period. The regional growth is attributed to strategic collaboration with a specialty pharmacy. 

• For instance, in January 2025, Norgine, a European specialist pharmaceutical company, collaborated with X4 Pharmaceuticals, Inc., and signed an exclusive licensing and supply agreement under which Norgine will commercialize mavorixafor in Australia and New Zealand following regulatory approvals.

Key Players Covered

The global WHIM syndrome market is consolidated with the presence of a limited companies and a large number of emerging companies.

The report includes the profiles of the following key players:

• X4 Pharmaceuticals (U.S.)
• Other Prominent Players

Key Industry Developments

• In April 2024, X4 Pharmaceutical Inc. received fast-track designation for Mavorixafor by the U.S. FDA for the treatment of WHIM syndrome, a rare immunodeficiency indication.
• In July 2019, X4 Pharmaceuticals received orphan drug designation from the European Commission for mavorixafor for the treatment of WHIM syndrome.
• In December 2018, X4 Pharmaceuticals presented additional Phase 2 clinical data demonstrating a positive safety profile and clinical activity of X4P‑001 in patients with WHIM syndrome, a rare primary immunodeficiency disease. The clinical results are being presented today in a poster session at the 60th American Society of Hematology (ASH) Annual Meeting taking place in San Diego.